Trials / Conditions / HER2-positive Early Breast Cancer

HER2-positive Early Breast Cancer

8 registered clinical trials studyying HER2-positive Early Breast Cancer — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib A NCT07340398	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2
Active Not Recruiting	NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Brea NCT05704829	West German Study Group	Phase 2
Recruiting	EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer NCT05883852	Fudan University	Phase 3
Active Not Recruiting	Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-po NCT05113251	AstraZeneca	Phase 3
Recruiting	Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients NCT04750122	Peking University People's Hospital	Phase 1 / Phase 2
Completed	A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the F NCT04024462	Hoffmann-La Roche	Phase 3
Completed	A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer NCT03989037	Shanghai Institute Of Biological Products	Phase 3
Completed	A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combi NCT03674112	Hoffmann-La Roche	Phase 2